human huvec umbilical vein endothelial cells  (ATCC)

Journal: PLOS Computational Biology

Article Title: Uncertainty-aware traction force microscopy

doi: 10.1371/journal.pcbi.1013079

Figure Lengend Snippet: ( A ) Membrane labeling of HUVEC monolayers with CellMask. ( B ) Corresponding fluorescent bead image (beads of size 0.2 μ m ). Arrows indicate bead-related image artifacts ( C ) PIV-UQ displacement field u PIV ( D ) PIV-UQ uncertainty map, σ u , P I V . White regions indicate “bad” PIV windows that were deleted and replaced as described in § 2.2. Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of bootstrapped PIV-UQ distribution. ( E ) Inferred mean marginal posterior traction stress, t ^ ( F ) Marginal posterior traction stress uncertainty field ( σ t ). Uncertainty arrows denote the pointwise angular uncertainty corresponding to 1 circular std. dev. of marginal posterior p ( t | u h ) . Scale bar : 25 μ m

Article Snippet: Human vascular umbilical endothelial vein cells (HUVECs) (Cell Applications) were cultured in M199 (Gibco) supplemented with 10 % (v/v) endothelial growth medium (Cell Applications), 10 % (v/v) fetal bovine serum (Gibco), and 1 % penicillin-streptomycin (Gibco).

Techniques: Membrane, Labeling

Journal: Cell Reports Medicine

Article Title: Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy

doi: 10.1016/j.xcrm.2025.102528

Figure Lengend Snippet: Preparation, characterization, ROS scavenging, and biocompatibility of VPNS@P (A) Schematic of exfoliation and PEGylation of violet phosphorus (VP) to prepare VPNS@P from bulk VP. (B) Transmission electron microscopy (TEM) image of VPNS@P. Scale bar, 100 nm. (C) Hydrodynamic size distribution of VPNS@P measured by dynamic light scattering (DLS). (D and E) Atomic force microscopy (AFM) image (D) and thickness profile (E) of VPNS@P. Scale bar, 100 nm. (F) Raman scattering spectra of VPNS@P. (G) Time-course DLS measurements of VPNS@P incubated in PBS or DMEM supplemented with 10% fetal bovine serum (FBS) over 7 days ( n = 3 independent samples). (H–J) Scavenging capability of VPNS@P ( n = 5 independent samples) toward H 2 O 2 (H), ·OH (I), and O 2 ·− (J). (K–M) Biocompatibility of VPNS@P in vitro . Cell viabilities of RAW264.7 (K), mouse aortic vascular smooth muscle cells (MOVASs) (L), and human umbilical vein endothelial cells (HUVECs) (M) were examined with a CCK-8 assay ( n = 3 biologically independent samples). Data were analyzed using one-way ANOVA with a Dunnett’s T3 post hoc test and are shown as the mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001. ns, not significant.

Article Snippet: Human: HUVEC umbilical vein endothelial cells , ATCC , CRL-1730; RRID: CVCL_2959.

Techniques: Transmission Assay, Electron Microscopy, Microscopy, Incubation, In Vitro, CCK-8 Assay

Journal: Pharmaceutics

Article Title: Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing †

doi: 10.3390/pharmaceutics17040526

Figure Lengend Snippet: rhMG53 inhibits vascular endothelial cell migration and tube formation. ( A ) rhMG53 did not induce cellular toxicity in HUVEC up to 100 μg/mL ( n = 5; ** p = 0.01). ( B ) Representative photomicrographs 24 h after scratch wounding, HUVEC treated with 50 μg/mL rhMG53 had significantly less migration and proliferation compared to control ( n = 9). Magnification 4×. ( C ) Quantification of the scratch area remaining at 24 h (**** p < 0.0001). ( D ) Representative photomicrographs and quantification of tube formation when HUVEC was seeded on Matrigel, followed by treatment with VEGF (10 ng/mL) with or without rhMG53 (50 μg/mL) for 18 h. rhMG53 significantly reduced tube length in VEGF-treated HUVEC ( n = 4; ** p = 0.0029). Magnification 4×. ( E ) HUVEC treated with IL-1B (10 ng/mL) with or without rhMG53 have decreased pSTAT3 protein expression; when normalized to total STAT3 expression, rhMG53 significantly (** p = 0.0084) decreased pSTAT3 ( n = 4). Statistical significance was assessed with the Kruskal–Wallis nonparametric test.

Article Snippet: Normal primary human vascular endothelial cells (HUVEC) were purchased from ATCC (Manassas, VA, USA) and grown in F-12K medium containing endothelial cell growth supplement.

Techniques: Migration, Control, Expressing